Paradigm Biocapital Advisors LP Alpine Immune Sciences, Inc. Transaction History

Paradigm Biocapital Advisors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.75 - $41.6 $18.7 Million - $43.9 Million	-1,055,580 Reduced 33.23%	2,121,163 $84.1 Million
Q4 2023 Feb 14, 2024	BUY	$8.54 - $20.22 $6.45 Million - $15.3 Million	755,000 Added 31.18%	3,176,743 $60.5 Million
Q3 2023 Nov 14, 2023	SELL	$10.13 - $13.98 $22,468 - $31,007	-2,218 Reduced 0.09%	2,421,743 $27.7 Million
Q2 2023 Aug 14, 2023	BUY	$6.84 - $11.91 $727,276 - $1.27 Million	106,327 Added 4.59%	2,423,961 $24.9 Million
Q4 2022 Feb 14, 2023	BUY	$5.45 - $7.35 $560,870 - $756,403	102,912 Added 4.65%	2,317,634 $17 Million
Q3 2022 Nov 14, 2022	BUY	$6.89 - $9.39 $9.56 Million - $13 Million	1,387,943 Added 167.87%	2,214,722 $15.9 Million
Q2 2022 Aug 15, 2022	BUY	$6.71 - $9.52 $3.29 Million - $4.67 Million	490,550 Added 145.9%	826,779 $7.04 Million
Q1 2022 May 16, 2022	BUY	$6.41 - $13.89 $2.16 Million - $4.67 Million	336,229 New	336,229 $3.02 Million

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.